Skip to main content
Log in

The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Phenprocoumon was given orally to 9 patients with biopsy proven liver cirrhosis (dose range 0.12–0.25 mg/kg) and to 7 healthy volunteers (0.23 mg/kg). Concentrations of phenprocoumon were determined using HPLC in plasma and urine samples obtained for 6–7 days after drug administration. The binding of [3H]-phenprocoumon in plasma from all subjects was determined by equilibrium dialysis. Antipyrine plasma concentrations were determined spectrophotometrically following oral administration of antipyrine (1200 mg). The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64±0.16 ml/h/kg mean ± SEM) than in the healthy volunteers (0.90±0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144±14 ml/h/kg) compared with normal (113±11 ml/h/kg). In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5±2.9 ml/h/kg) compared with normal (35.6±3.9 ml/h/kg). The metabolic clearance of phenprocoumon via glucuronidation, is relatively unaffected during cirrhosis compared with antipyrine clearance via oxidation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andreasen PB, Ranek L, Statland BE, Tygstrup N (1974) Clearance of antipyrine. Dependence of quantitative liver function. Europ J Clin Invest 4: 129–134

    Google Scholar 

  • Brodie BB, Axelrod J, Soberman R, Levy BB (1949) The estimation of antipyrine in biological materials. J Biol Chem 179: 25–29

    Google Scholar 

  • Heni G, Lehnhardt G, Glogner P (1976) Eliminationkinetik von Phenprocoumon (Marcumar) bei Leberzirrhose und nach Vorbehandlung mit Phenobarbital. Int J Clin Pharmacol 13: 253–261

    Google Scholar 

  • Kitteringham NR, Büstgens L, Brundert E, Mineshita S, Ohnhaus EE (1983) Pharmacokinetics of phenprocoun in patients with liver cirrhosis. Br J Clin Pharmacol 15: 590 P

  • Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA (1979) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26: 221–227

    Google Scholar 

  • Koch-Weser J, Sellers EM (1971) Drug interactions with coumarin anticoagulants. New Engl J Med 285: 487–498

    Google Scholar 

  • Kraus JW, Desmond PV, Marshall SP, Johnson RF, Schenker S, Wilkinson GR (1978) Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 24: 411–419

    Google Scholar 

  • Meinertz Th, Gilfrich HJ, Groth U, Jonen HG, Jähnchen E (1977) Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther 21: 731–735

    Google Scholar 

  • Ohnhaus EE, Münch U, Meier J (1976) Vergleichende Untersuchung zur Elimination von Pindolol und Antipyrin bei Patienten mit Lebererkrankungen. Schweiz Med Wochenschr 106: 1748–1750

    Google Scholar 

  • Ohnhaus EE, Münch U, Meier J (1982) Elimination of pindolol in liver disease. Eur J Clin Pharmacol 22: 247–251

    Google Scholar 

  • Sellers EM, Greenblatt DJ, Giles HC, Narango CA, Kaplan H, McLeod SM (1979) Chlordiazepoxide and oxazepam diposition in cirrhosis. Clin Pharmacol Ther 26: 240–246

    Google Scholar 

  • Shull HJ, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84: 420–425

    Google Scholar 

  • Sotaniemi EA, Anttila M, Pelkonen OR, Järvensivu P, Sundquist A (1979) Plasma clearance of propranolol and sotalol and hepatic drug metabolizing enzyme activity. Clin Pharmacol Ther 26: 153–161

    Google Scholar 

  • Tschanz C, Wilson RL, Shand DG (1983) The effects of cirrhosis on temazepam elimination. Clin Pharmacol Ther 33: 218

    Google Scholar 

  • Vesell ES (1979) The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 26: 275–286

    Google Scholar 

  • Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M (1977) Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21: 301–309

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitteringham, N.R., Büstgens, L., Brundert, E. et al. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. Eur J Clin Pharmacol 26, 65–70 (1984). https://doi.org/10.1007/BF00546711

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00546711

Key words

Navigation